PE66198A1 - Inhibicion de las metaloproteinasas de matriz por acidos 2-(omega-aroilalquil)-4-biaril-4-oxobutiricos - Google Patents

Inhibicion de las metaloproteinasas de matriz por acidos 2-(omega-aroilalquil)-4-biaril-4-oxobutiricos

Info

Publication number
PE66198A1
PE66198A1 PE1997000364A PE00036497A PE66198A1 PE 66198 A1 PE66198 A1 PE 66198A1 PE 1997000364 A PE1997000364 A PE 1997000364A PE 00036497 A PE00036497 A PE 00036497A PE 66198 A1 PE66198 A1 PE 66198A1
Authority
PE
Peru
Prior art keywords
formula
oxobutiricos
biaril
aroilalquil
omega
Prior art date
Application number
PE1997000364A
Other languages
English (en)
Inventor
Margaret A Popp
David S Hartsough
William Scott
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE66198A1 publication Critical patent/PE66198A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I) Y A LOS COMPUESTOS INTERMEDIOS DE FORMULA (II), EN DONDE: v ES 1; 2; 3 o 4; y Y x SON 0; 1 o 2; DE TAL MANERA QUE CUANDO y ES 0, SE TRATE DE UNA CADENA LINEAL DE ALQUILO; w ES 0; 1; 2 o 3; "Z" ES CO; "T" ES DE PREFERENCIA Cl; R2 ES H, ALQUILO C1-C6 O ARILO C6-C10, ENTRE OTROS; R20 ES ALQUILO C1-C5, ALCOXI C1-C5, HALOGENO O ARILOXI, ENTRE OTROS; R21 ES R2 O ALILO. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO INHIBIDORES DE LAS METALOPROTEASAS DE LA MATRIZ (MMP) QUE POSEEN MEJOR BIODISPONIBILIDAD Y ESTABILIDAD BIOLOGICA, SIENDO UTILES PARA: (a) MITIGAR LOS EFECTOS DE LA OSTEOARTRITIS O ARTRITIS REUMATOIDEA, ENTRE OTROS; (b) RETARDAR LAS METASTASIS DE TUMORES O LA PERDIDA DEGENERATIVA DE CARTILAGO POSTERIOR A UNA LESION ARTICULAR TRAUMATICA; (c) REDUCIR LA TROMBOSIS CORONARIA; O (d) PRACTICAR EL CONTROL DE LA NATALIDAD
PE1997000364A 1996-05-15 1997-05-12 Inhibicion de las metaloproteinasas de matriz por acidos 2-(omega-aroilalquil)-4-biaril-4-oxobutiricos PE66198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64502996A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
PE66198A1 true PE66198A1 (es) 1998-10-23

Family

ID=24587374

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000364A PE66198A1 (es) 1996-05-15 1997-05-12 Inhibicion de las metaloproteinasas de matriz por acidos 2-(omega-aroilalquil)-4-biaril-4-oxobutiricos

Country Status (22)

Country Link
EP (1) EP0904260B1 (es)
JP (1) JP3524556B2 (es)
CN (1) CN1119313C (es)
AR (1) AR007099A1 (es)
AT (1) ATE224350T1 (es)
AU (1) AU715877B2 (es)
BR (1) BR9709078A (es)
CA (1) CA2254750C (es)
CO (1) CO5011071A1 (es)
DE (1) DE69715619T2 (es)
ES (1) ES2184092T3 (es)
HN (1) HN1997000070A (es)
HR (1) HRP970242A2 (es)
ID (1) ID17938A (es)
PA (1) PA8429601A1 (es)
PE (1) PE66198A1 (es)
SV (1) SV1997000038A (es)
TN (1) TNSN97081A1 (es)
TW (1) TW457231B (es)
WO (1) WO1997043240A1 (es)
YU (1) YU18397A (es)
ZA (1) ZA974028B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
WO2015150362A2 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung
WO2015150350A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen
WO2015150363A1 (de) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
CN116687925B (zh) * 2022-11-04 2024-10-22 中国科学院遗传与发育生物学研究所 一种侵蚀性蛋白酶抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS243570B1 (en) * 1984-08-31 1986-06-12 Miroslav Kuchar Omega-aryloxoalkane acids
GB9101468D0 (en) * 1991-01-23 1991-03-06 Ciba Geigy Coating compositions
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
PA8429601A1 (es) 2000-05-24
TNSN97081A1 (fr) 2005-03-15
CA2254750A1 (en) 1997-11-20
ES2184092T3 (es) 2003-04-01
YU18397A (en) 1999-11-22
SV1997000038A (es) 1998-09-01
CN1119313C (zh) 2003-08-27
WO1997043240A1 (en) 1997-11-20
DE69715619T2 (de) 2003-01-16
EP0904260A1 (en) 1999-03-31
TW457231B (en) 2001-10-01
HN1997000070A (es) 1997-09-08
DE69715619D1 (de) 2002-10-24
CO5011071A1 (es) 2001-02-28
CA2254750C (en) 2003-09-30
JP3524556B2 (ja) 2004-05-10
EP0904260B1 (en) 2002-09-18
CN1234791A (zh) 1999-11-10
AR007099A1 (es) 1999-10-13
ATE224350T1 (de) 2002-10-15
ID17938A (id) 1998-02-12
ZA974028B (en) 1998-02-19
AU715877B2 (en) 2000-02-10
BR9709078A (pt) 1999-08-03
AU3010497A (en) 1997-12-05
JP2001509783A (ja) 2001-07-24
HRP970242A2 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
CY1118652T1 (el) Συνθεσεις που περιεχουν φθοριο-υποκατεστημενες ολεφινες
PE66898A1 (es) Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos
AR020787A1 (es) Derivados de acidos diaminopropionicos
NO20023043D0 (no) Substituerte oksazolidinoner og deres anvendelse innenfor feltet blodkoagulasjon
ES2067314T3 (es) 3-benzacepin-zonas sustituidas por un grupo benzociclobutilo o indanil-alquil-amino-alquilo, utiles en el tratamiento de las afecciones cardiovasculares.
BR0010555A (pt) Inibidores de neuraminidases
PE20020859A1 (es) Derivados del acido isoftalico como inhibidores de metaloproteinasas de la matriz
PE88198A1 (es) Inhibidores de metaloproteasas matriciales basados en fosfinatos
FR2812551B1 (fr) Forme pharmaceutique comprenant un materiau support a base de methylidene malonate et un facteur de regulation cellulaire
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
NO20021229L (no) Benzamider og relaterte inhibitorer for faktor Xa
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
BR9713462A (pt) Métodos para produção de compostos carotenóides e óleos especiais em sementes de plantas.
RS51136B (sr) Supstituisani pirolopiridini, kompozicije koje ih sadrže, postupak za njihovo dobijanje i upotreba
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
DE69922703D1 (de) Ureido-thiobuttersäurederivate als ppar-agonisten
PE66198A1 (es) Inhibicion de las metaloproteinasas de matriz por acidos 2-(omega-aroilalquil)-4-biaril-4-oxobutiricos
EP1509250A4 (en) METHOD, COMPOSITIONS AND PRODUCTION OBJECTS FOR MODULATING BONE GROWTH
BR0110087A (pt) Compostos para modular proliferação celular
ES2155621T3 (es) Derivados azo del acido 5-aminosalicilico para el tratamiento de la enfermedad inflamatoria intestinal.
PE66298A1 (es) Inhibicion de las metaloproteasas de matriz por compuestos de fenetileno sustituido
NZ514758A (en) Cyclobutenedione compounds to treat conditions in which endothelial dysfunction is known
CO6160311A2 (es) Nuevos derivados de fluoreno composiciones que los contienen y utilizacion como inhibidores de la proteina chaperona hsp90
TR199900153T2 (xx) H�cre �o�almas�n� �nlemek i�in ikame edilmi� bisindolilmaleimitler.
ES2082877T3 (es) Sales de derivados de triacina con acidos oxigenados de fosforo.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed